Who Exports Pyrazinamide from India — 90 Suppliers Behind a $962.4M Market
India's pyrazinamide export market is supplied by 90 active exporters who collectively shipped $962.4M across 1,459 shipments. LUPIN LIMITED leads with a 86.6% market share, followed by MACLEODS PHARMACEUTICALS LTD and MACLEODS PHARMACEUTICALS LIMITED. The top 5 suppliers together control 99.4% of total export value, reflecting a concentrated market structure.
Top Pyrazinamide Exporters from India — Ranked by Export Value
LUPIN LIMITED is the leading pyrazinamide exporter from India, holding a 86.6% share of the $962.4M market across 1,459 shipments from 90 exporters. The top 5 suppliers — LUPIN LIMITED, MACLEODS PHARMACEUTICALS LTD, MACLEODS PHARMACEUTICALS LIMITED, MANEESH PHARMACEUTICALS LIMITED, SVIZERA LABS PRIVATE LIMITED — collectively control 99.4% of total export value, indicating a highly concentrated market. Individual shares are: LUPIN LIMITED (86.6%), MACLEODS PHARMACEUTICALS LTD (11.0%), MACLEODS PHARMACEUTICALS LIMITED (0.8%), MANEESH PHARMACEUTICALS LIMITED (0.7%), SVIZERA LABS PRIVATE LIMITED (0.4%).
Top Pyrazinamide Exporters from India
Ranked by export value · 90 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | LUPIN LIMITED 4 FDC TABLET ALU ALUBRA-1BOXX15X6T | $833.0M | 49 | 86.6% |
| 2 | MACLEODS PHARMACEUTICALS LTD 4 FDC TABLET ALU ALUBRA-1BOXX15X6TPYRAZINAMIDE PS: 02 VAILS | $105.7M | 84 | 11.0% |
| 3 | MACLEODS PHARMACEUTICALS LIMITED 4 FDC TABLET ALU ALUBRA-1BOXX15X6TPYRAZINAMIDE PS: 02 VAILS | $8.0M | 51 | 0.8% |
| 4 | MANEESH PHARMACEUTICALS LIMITED | $6.5M | 24 | 0.7% |
| 5 | SVIZERA LABS PRIVATE LIMITED | $3.7M | 12 | 0.4% |
| 6 | MICRO LABS LIMITED 4 FDC TABLET ALU ALUBRA-1BOXX15X6T | $1.8M | 23 | 0.2% |
| 7 | MANEESH PHARMACEUTICALS LTD | $1.2M | 5 | 0.1% |
| 8 | UNILINK PHARMA PRIVATE LIMITED | $291.1K | 2 | 0.0% |
| 9 | OMNICALS PHARMA PRIVATE LIMITED | $275.2K | 2 | 0.0% |
| 10 | SIMPEX PHARMA PRIVATE LIMITED | $194.8K | 1 | 0.0% |
| 11 | M. J. BIOPHARM PRIVATE LIMITED | $171.1K | 1 | 0.0% |
| 12 | DEUTSCHE LABS INC. | $158.2K | 1 | 0.0% |
| 13 | PHAR & VIDE 4 FDC TABLET ALU ALUBRA-1BOXX15X6TPYRAZINAMIDE PS: 02 VAILS | $138.0K | 2 | 0.0% |
| 14 | AVALOR HEALTH CARE PRIVATE LIMITED | $113.6K | 1 | 0.0% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Pyrazinamide exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| LUPIN LIMITED | Approved | Yes (April 2025) | Yes | Data not specified | Lupin's Anakapalli facility received WHO-GMP certification in April 2025. (extra |
| MACLEODS PHARMACEUTICALS LIMITED | Approved | Yes (June 2023) | Yes | 100 approved as of August 31, 2023 | Macleods' Sarigam facility received WHO-GMP certification in June 2023. (extrane |
| MICRO LABS LIMITED | Approved | Yes (December 2022) | Data not specif | Data not specified | Micro Labs' Bengaluru facility received WHO-GMP certification in December 2022. |
TransData Nexus reviewed the regulatory standing of 3 leading Pyrazinamide exporters from India. 3 hold US FDA facility approvals, 3 maintain WHO-GMP certification, and 2 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Pyrazinamide sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes approximately 40% of the country's bulk drug production. The city hosts over 2,000 pharmaceutical companies, including major players like Dr. Reddy's Laboratories and Aurobindo Pharma. The establishment of Genome Valley, a premier biotech cluster, has further solidified Hyderabad's position as a hub for pharmaceutical research and manufacturing.
The city's robust infrastructure and skilled workforce make it a significant contributor to the production of active pharmaceutical ingredients (APIs), including those used in the formulation of Pyrazinamide. Hyderabad's strategic initiatives, such as the Hyderabad Pharma City project, aim to enhance its capacity in pharmaceutical manufacturing and exports.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations. Gujarat accounts for 33% of India's drug manufacturing and 28% of drug exports, with Ahmedabad and Vadodara being central to this output. The region is home to prominent companies like Alembic Pharmaceuticals, which specializes in formulations for various therapeutic areas.
Vadodara, in particular, has a strong presence in pharmaceutical manufacturing, with companies like Alembic Pharmaceuticals headquartered there. The city's industrial ecosystem supports the production of both APIs and finished dosage forms, contributing significantly to the export of pharmaceuticals, including Pyrazinamide.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates the export of pharmaceutical products to global markets. The region hosts several pharmaceutical companies that leverage the logistical advantages to distribute products like Pyrazinamide efficiently.
The proximity to international shipping routes and well-established infrastructure makes this cluster pivotal in the supply chain, ensuring timely delivery of pharmaceutical exports.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives. The region attracts numerous pharmaceutical companies seeking cost-effective production facilities. While it contributes to the overall pharmaceutical output, its role in the production and export of Pyrazinamide is less pronounced compared to other clusters.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 99.4% of Pyrazinamide exports, it's advisable to explore partnerships with emerging manufacturers in different clusters to mitigate supply chain risks.
- Leverage Hyderabad's API Strength: Collaborate with Hyderabad-based companies for sourcing high-quality APIs, capitalizing on the city's expertise in bulk drug production.
- Utilize Gujarat's Formulation Capabilities: Engage with manufacturers in the Ahmedabad-Vadodara region for finished dosage forms, benefiting from their specialization in pharmaceutical formulations.
- Optimize Logistics via Mumbai: Coordinate exports through the Mumbai-Thane-Raigad corridor to ensure efficient distribution and access to international markets.
By strategically engaging with these pharmaceutical clusters, TransData Nexus can enhance its supply chain resilience and optimize the sourcing and distribution of Pyrazinamide.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Pyrazinamide exporters from India
Lupin Limited — Lupin acquires two brands from Sanofi in Europe and Canada
Lupin's European subsidiary, Lupin Atlantis Holdings SA, completed the acquisition of Aarane™ in Germany and Nalcrom™ in Canada and the Netherlands from Sanofi. This acquisition enhances Lupin's respiratory business in Germany and expands its specialty portfolio. - IMPACT: This strategic move is expected to strengthen Lupin's global presence, potentially increasing its capacity to export Pyrazinamide.
Impact: This strategic move is expected to strengthen Lupin's global presence, potentially increasing its capacity to export Pyrazinamide.
Lupin Limited — Lupin acquires nine brands from Medical Nutritional Institute in South Africa
Lupin's South African subsidiary, Pharma Dynamics, acquired nine brands from the Medical Nutritional Institute SA, focusing on plant-based products for metabolic diseases. This acquisition broadens Lupin's product range in South Africa. - IMPACT: The expansion in South Africa may lead to increased production capabilities, potentially boosting Pyrazinamide exports.
Impact: The expansion in South Africa may lead to increased production capabilities, potentially boosting Pyrazinamide exports.
Lupin Limited — Lupin acquires UK-based Renascience Pharma for £12.3 million
Lupin's subsidiary, Lupin Healthcare (UK) Limited, acquired Renascience Pharma, a supplier of niche branded bio-generic products in the UK. This acquisition aims to strengthen Lupin's branded pharmaceuticals business in the UK. - IMPACT: The acquisition enhances Lupin's market presence in the UK, potentially leading to increased Pyrazinamide exports.
Impact: The acquisition enhances Lupin's market presence in the UK, potentially leading to increased Pyrazinamide exports.
Common Questions — Pyrazinamide Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which pyrazinamide supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, LUPIN LIMITED leads with 321 recorded shipments worth $833.0M. MACLEODS PHARMACEUTICALS LTD (361 shipments) and MACLEODS PHARMACEUTICALS LIMITED (143 shipments) are also established high-volume exporters.
Q How many pyrazinamide manufacturers are there in India?
India has 90 active pyrazinamide exporters with a combined export market of $962.4M across 1,459 shipments to 131 countries. The top 5 suppliers hold 99.4% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for pyrazinamide from India?
Average FOB unit price: $9.03 per unit, ranging from $0.00 to $202.61. Average shipment value: $659.6K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 90 verified Indian exporters of Pyrazinamide ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,459 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 131 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,459 Verified Shipments
90 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists